Leishmaniasis Research

 

  • Target disease: Visceral Leishmaniasis
  • Main Partners (since project start): Celgene Global Health, USA; Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; London School of Hygiene and Tropical Medicine, UK; WuXi AppTech, China; Sandexis, UK.
  • Project start: 2015
  • Funding (since project start): Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International.

 

Overall Objective: 

  • Select a pre‑clinical candidate from the CGH VL series for the treatment of visceral leishmaniasis.

 

The development of new, orally-active drug candidates providing options for entry into future Phase I clinical trials is a priority for DNDi Discovery. A novel series of heterocyclic compounds for visceral leishmaniasis has been optimized by Celgene in collaboration with London School of Hygiene and Tropical Medicine and Advinus, and with advice from DNDi.

An in vivo proof-of-concept has been achieved for this series. An intensive lead optimization programme is ongoing with Celgene to identify an optimized lead. 

 

Last update: February 2017